Antibiotics and Adverse Events in Patients with Pancreatic Cancer Treated with Gemcitabine: Looking for Novel Clinical and Preclinical Insights

Btissame El Hassouni; Alessandro Gregori; Jisce R Puik; Dongmei Deng; Geert Kazemier; Elisa Giovannetti

doi:10.1002/onco.13606

Antibiotics and Adverse Events in Patients with Pancreatic Cancer Treated with Gemcitabine: Looking for Novel Clinical and Preclinical Insights

Oncologist. 2021 Dec;26(12):e2306-e2307. doi: 10.1002/onco.13606. Epub 2020 Dec 7.

Authors

Btissame El Hassouni¹, Alessandro Gregori¹, Jisce R Puik², Dongmei Deng³, Geert Kazemier⁴, Elisa Giovannetti^{1

5}

Affiliations

¹ Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University Amsterdam, The Netherlands.
² Departments of Medical Oncology and Surgery, Cancer Center Amsterdam, Amsterdam UMC, VU University Amsterdam, The Netherlands.
³ Department of Preventive Dentistry, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University Amsterdam, Amsterdam, The Netherlands.
⁴ Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, VU University Amsterdam, The Netherlands.
⁵ Fondazione Pisana per la Scienza, Pisa, Italy.

Abstract

This letter to the editor remarks on a recently published article reporting on gemcitabine‐related adverse events associated with antibacterial use, focusing on key points for further consideration.

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Anti-Bacterial Agents* / adverse effects
Deoxycytidine / adverse effects
Deoxycytidine / analogs & derivatives
Gemcitabine
Humans
Pancreatic Neoplasms* / drug therapy

Substances

Anti-Bacterial Agents
Deoxycytidine
Gemcitabine